The vaccine is made by Inovio Pharmaceuticals of Plymouth Meeting, Pa., and GeneOne Life Science, of Seoul, South Korea. The working name for the vaccine is GLS-5700. The phase I trial will evaluate the safety and efficacy of the vaccine in 40 healthy subjects. In preclinical animal models, the vaccine produced a robust antibody and T cell response.
J. Joseph Kim, PhD, CEO of Inovio, said, “We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers.”
Federal health officials have previously stated that determining the efficacy of a Zika vaccine could take several years.
More articles on the Zika virus:
FDA authorizes emergency use of in-vitro devices to detect Zika
6 cases of Zika-related birth defects reported in US
Researchers on a medical road trip through Brazil are using mobile labs to track Zika
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
